使用CiteSpace对克罗恩病中使用ustekinumab的图书统计和视觉分析
Yi Chen1, Jiaqi Zhang1, Junling Wu1
1Department of Gastroenterology and Hepatology, First Medical Center, Chinese PLA General Hospital, Beijing, China.
Frontiers in pharmacology
|January 25, 2024
概括
乌斯特基努马布 (UST) 是克罗恩病 (CD) 的有效生物疗法. 研究趋势显示,重点关注其有效性,安全性和患者监测的生物标志物.
科学领域:
- 免疫学和胃肠道学
- 生物疗法 生物疗法
- 图书统计分析 图书统计分析
背景情况:
- 克罗恩氏病 (CD) 治疗正在使用新型生物药物发展.
- 针对IL-12/23的单克隆抗体 Ustekinumab (UST) 在CD治疗中显示出有前途.
- 需要对UST研究现状和趋势进行全面的概述.
研究的目的:
- 视觉分析乌斯特基努马布 (UST) 在克罗恩病 (CD) 研究的现状和趋势.
- 确定该领域的领先研究人员和机构.
- 识别研究缺陷,并为未来的研究优先事项提供信息.
主要方法:
- 从2008年到2022年对479篇关于克罗恩氏病 (CD) 中的乌斯特基努马布 (UST) 的文章进行了图书统计分析.
- 数据来源于科学网络核心集合数据库.
- 使用CiteSpace软件进行的知识映射和可视化.
主要成果:
- 出版物来自51个国家,美国,加拿大和英国是主要贡献者.
- 关键的研究主题包括UST的临床疗效,安全性和在弱势群体中的使用.
- 便calprotectin在2020年成为一个重要的生物标志物,这表明重点是监测治疗反应和识别与USTT相关的生物标志物.
结论:
- 针对CD的UST临床研究正在增加,重点关注疗效,安全性和生物标志物.
- 在其他治疗方法失败后,UST是耐火性CD患者的安全和有效选择.
- UST仍然是未来克罗恩病研究的重要领域.
相关概念视频
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
120
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
120
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
137
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
137
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
166
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
166
01:29Inflammatory Bowel Disease IV: Pharmacological Management
127
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
127
01:29Drugs for Treatment of Ulcerative Colitis in IBD
141
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
141